APOE effect on Alzheimer's disease biomarkers in older adults with significant memory concern

作者：Risacher Shannon L; Kim Sungeun; Nho Kwangsik; Foroud Tatiana; Shen Li; Petersen Ronald C; Jack Clifford R Jr; Beckett Laurel A; Aisen Paul S; Koeppe Robert A; Jagust William J; Shaw Leslie M; Trojanowski John Q; Weiner Michael W; Saykin Andrew J^*

来源：Alzheimer's and Dementia, 2015, 11(12): 1417-1429.

DOI：10.1016/j.jalz.2015.03.003

• Significant memory concern
• SMC
• Subjective cognitive decline
• SCD
• Apolipoprotein E
• APOE
• Neuroimaging
• [F-18] Florbetapir PET
• [F-18] Fluorodeoxyglucose
• FDG
• PET
• Structural magnetic resonance imaging (MRI)
• Cerebrospinal fluid
• CSF
• Alzheimer's Disease Neuroimaging Initiative
• ADNI

Introduction: This study assessed apolipoprotein E (APOE) epsilon 4 carrier status effects on Alzheimer's disease imaging and cerebrospinal fluid (CSF) biomarkers in cognitively normal older adults with significant memory concerns (SMC).
Methods: Cognitively normal, SMC, and early mild cognitive impairment participants from Alzheimer's Disease Neuroimaging Initiative were divided by APOE epsilon 4 carrier status. Diagnostic and APOE effects were evaluated with emphasis on SMC. Additional analyses in SMC evaluated the effect of the interaction between APOE and [F-18]Florbetapir amyloid positivity on CSF biomarkers.
Results: SMC epsilon 4+ showed greater amyloid deposition than SMC epsilon 4-, but no hypometabolism or medial temporal lobe (MTL) atrophy. SMC epsilon 4+ showed lower amyloid beta 1-42 and higher tau/p-tau than epsilon 4-, which was most abnormal in APOE epsilon 4+ and cerebral amyloid positive SMC.
Discussion: SMC APOE epsilon 4+ show abnormal changes in amyloid and tau biomarkers, but no hypometabolism or MTL neurodegeneration, reflecting the at-risk nature of the SMC group and the importance of APOE in mediating this risk.

• 出版日期2015-12